Pregled bibliografske jedinice broj: 1050650
Challenges in Manipulating Immune System to Treat Prostate Cancer
Challenges in Manipulating Immune System to Treat Prostate Cancer // Acta clinica Croatica, 58 (2019), Suppl. 2; 76-80 (recenziran, članak, stručni)
CROSBI ID: 1050650 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Challenges in Manipulating Immune System to Treat
Prostate Cancer
Autori
Šamija, Ivan ; Fröbe, Ana
Izvornik
Acta clinica Croatica (0353-9466) 58
(2019), Suppl. 2;
76-80
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, stručni
Ključne riječi
Prostate Cancer ; Immunotherapy ; Cancer Vaccines ; Immune Checkpoint Inhibitors ; Tumor Immune Evasion
Sažetak
First cancer vaccine that was approved for routine therapy was sipuleucel-T for treatment of patients with metastatic castration resistant prostate cancer. However, other immunotherapy drugs evaluated in prostate cancer, particularly immune checkpoint inhibitors, have failed to show therapeutic effect. There are several potential explanations for lack of response of prostate cancer to these drugs. These explanations, which are related to specific genetic (e.g. low mutational burden) and immunological (e.g. immunosuppressive tumor immune microenvironment) background of prostate cancer are discussed in this review. Also, new therapeutic strategies to overcome prostate cancer immunotherapy resistance and to select subgroups of patients that could benefit from immunotherapy are outlined.
Izvorni jezik
Engleski
Znanstvena područja
Biologija, Temeljne medicinske znanosti, Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Stomatološki fakultet, Zagreb,
KBC "Sestre Milosrdnice"
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
